Year: 2021

news_6

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

Approval Based on Results From CLEAR/KEYNOTE-581 Trial Demonstrating KEYTRUDA Plus LENVIMA Significantly Reduced the Risk of Disease Progression or Death...

news_6

Asia-Pacific Soft Tissue Repair Market to 2028 – Demand for Soft Tissue Repair Products Catering to Sports-Related Injuries Presents Opportunities – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Soft Tissue Repair Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. Based on this analysis, the...